



## NEONATAL MEDICATION PROTOCOLS

**PENTOXIFYLLINE ( FOR NEBULISATION)**  
Created by: NCCU  
Date for review: Oct 2016

NCCU Clinical Guidelines  
KEMH/PMH  
Perth, Western Australia

<b>DRUG:</b>	<b>PENTOXIFYLLINE ( FOR NEBULISATION)</b>
<b>PRESENTATION:</b>	Ampoule: 100mg/5mL Pre-packed syringes from Pharmacy contain excess solution
<b>ACTION &amp; INDICATION:</b>	A vasodilator used in the treatment of peripheral and cerebral vascular disorders. May reduce blood viscosity and improve blood flow by altering the rheology of red blood cells. Inhibits neutrophil activation and adhesion and platelet aggregation. Rescue for chronic lung disease
<b>DOSE:</b>	For nebulisation: <b>Spontaneously breathing:</b> 20mg/kg/dose every six hours for 10 days <b>Intubated:</b> 10mg/kg/dose every six hours for 10 days If needed, the 10 day course may be repeated after a gap of five days.
<b>PREPARATION:</b>	Nebulisation: Diluent : Sodium Chloride 0.9% Dilute to 2mL (or an appropriate volume)
<b>ADMINISTRATION:</b>	Nebulisation The expiratory block of ventilators should be changed on a weekly basis when nebulised drugs are used.
<b>ADVERSE EFFECTS:</b>	Flushes, pruritus, urticaria GI effects -nausea, vomiting, diarrhoea Cardiac arrhythmias Intrahepatic cholestasis, transaminase elevation Anaphylactic reaction (rare)
<b>COMMENTS:</b>	Must not be used in patients with increased risk of bleeding SAS approval must be obtained for use of this medication.
<b>REFERENCES:</b>	Lauterbach et al. Acta Paediatrica Suppl 444:20-22.2004 Pediatric Dosage Handbook 17 <sup>th</sup> Ed
<b>DATE:</b>	October 2013